Pancreatic Cancer Research

ResearcherSir Run Run Shaw HospitalActive in the last 2 years

Guoping Ding

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2964-0306; OpenAlex author ID A5016361588. Sources: OpenAlex.

Their work

Papers
25 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 5 papers · 2019: 5 papers · 2020: 4 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper

Papers 25

  1. Correction: Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Co-author DOI 10.1038/s41419-023-06399-3↗
  2. Identification of exosomal miR-484 role in reprogramming mitochondrial metabolism in pancreatic cancer through Wnt/MAPK axis control. Last author DOI 10.1016/j.phrs.2023.106980↗
  3. Post-translational modification of CDK1-STAT3 signaling by fisetin suppresses pancreatic cancer stem cell properties. Co-author DOI 10.1186/s13578-023-01118-z↗
  4. ZC3H13-mediated N6-methyladenosine modification of PHF10 is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.013↗
  5. Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation. Co-author DOI 10.1038/s41419-020-03019-2↗
  6. Pancreatic cancer-derived exosomes induce apoptosis of T lymphocytes through the p38 MAPK-mediated endoplasmic reticulum stress. Co-author DOI 10.1096/fj.201902186r↗
  7. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. Co-author DOI 10.1136/jitc-2019-000308↗
  8. Elevated expression of exosomal microRNA-21 as a potential biomarker for the early diagnosis of pancreatic cancer using a tethered cationic lipoplex nanopartic… First author DOI 10.3892/ol.2020.11302↗
  9. The distinct role of CD73 in the progression of pancreatic cancer. Co-author DOI 10.1007/s00109-018-01742-0↗
  10. Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Co-author DOI 10.1038/s41419-019-1366-y↗
  11. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. Co-author DOI 10.1186/s12885-019-6145-8↗
  12. Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis. Co-author DOI 10.7150/jca.27405↗
  13. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.31191↗
  14. Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF-κB Signaling Pathway. First author DOI 10.1089/jir.2018.0070↗
  15. IFN-γ induces the upregulation of RFXAP via inhibition of miR-212-3p in pancreatic cancer cells: A novel mechanism for IFN-γ response. Co-author DOI 10.3892/ol.2018.7777↗
  16. Down-expression of CD36 in pancreatic adenocarcinoma and its correlation with clinicopathological features and prognosis. Co-author DOI 10.7150/jca.21046↗
  17. High Expression of P38α and Preoperative Carbohydrate Antigen 19-9 Indicate Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.21683↗
  18. Integrated Analysis of Long Non-Coding RNA and mRNA Expression Profile in Pancreatic Cancer Derived Exosomes Treated Dendritic Cells by Microarray Analysis. Co-author DOI 10.7150/jca.21749↗
  19. A novel scoring system to analyze combined effect of lifestyle factors on pancreatic cancer risk: a retrospective case-control study. First author DOI 10.1038/s41598-017-13182-w↗
  20. Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3233/cbm-160671↗
  21. Increasing the immune activity of exosomes: the effect of miRNA-depleted exosome proteins on activating dendritic cell/cytokine-induced killer cells against pa… Co-author DOI 10.1631/jzus.b1500305↗
  22. Overexpressions of DLL4 and CD105 are Associated with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12253-015-9937-4↗
  23. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Co-author DOI 10.18632/oncotarget.4924↗
  24. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. Co-author DOI 10.1016/j.cellimm.2014.09.004↗
  25. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. First author DOI 10.1186/1477-7819-11-219↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liping Cao · 17 shared papers, 2016–2023 · strength 1.86
  2. Shengnan Jia · 12 shared papers, 2018–2024 · strength 1.52
  3. Liangjing Zhou · 11 shared papers, 2014–2022 · strength 1.00
  4. Xiaodong Xu · 7 shared papers, 2018–2024 · strength 0.97
  5. Liping Cao · 7 shared papers, 2013–2024 · strength 0.69
  6. Mingjie Zhang · 5 shared papers, 2018–2020 · strength 0.51
  7. Tao Shen · 4 shared papers, 2018–2020 · strength 0.45
  8. Zhengrong Wu · 5 shared papers, 2015–2020 · strength 0.45
  9. Xiaofan Pu · 3 shared papers, 2020–2023 · strength 0.44
  10. Zhengrong Wu · 4 shared papers, 2017–2019 · strength 0.41
  11. Jionghuang Chen · 5 shared papers, 2013–2018 · strength 0.33
  12. Guixing Jiang · 4 shared papers, 2015–2018 · strength 0.30
  13. Tianshu Pang · 2 shared papers, 2017–2022 · strength 0.23
  14. Weihua Yu · 2 shared papers, 2019 · strength 0.20
  15. Ting Zhao · 2 shared papers, 2018–2019 · strength 0.20
  16. Yuelong Liang · 1 shared paper, 2023 · strength 0.18
  17. Yiyin Zhang · 1 shared paper, 2023 · strength 0.18
  18. Tianyu Lin · 1 shared paper, 2023 · strength 0.18
  19. Yimin Ding · 1 shared paper, 2023 · strength 0.18
  20. Chaojie Huang · 1 shared paper, 2022 · strength 0.15
  21. Chaolei Zhang · 1 shared paper, 2022 · strength 0.15
  22. Risheng Que · 2 shared papers, 2013–2016 · strength 0.13
  23. Dongnan Ping · 1 shared paper, 2020 · strength 0.12
  24. Dan Li · 1 shared paper, 2020 · strength 0.12
  25. Xu Dong Sun · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.